post issue newspaper advertisements under Regulation 92
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dr Lalchandani Labs Ltd has submitted copies of newspaper advertisements published on March 6, 2026, in Financial Express (English, all editions) and Jansatta (Hindi, all editions), in compliance with SEBI ICDR Regulation 92 and LODR Regulation 30. The advertisements disclose post-issue details including subscription figures, basis of allotment, number, value, and percentage of all applications (including ASBA), and details of successful allottees. This indicates the company has recently completed a public issue or rights issue. The filing was signed by Arjan Lal Chandani, Managing Director (DIN: 07014579), from Delhi.
This is a routine post-issue compliance filing confirming completion of allotment for a public issue. It provides transparency to investors about subscription and allotment details but is unlikely to cause any immediate stock price movement, as it is procedural in nature following an already-completed issue.